Chinese Herbal Preparation CH-100 in treatment of Chronic Hepatitis

J Gastroenterol Hepatol 1998 Mar;13(3):244-247
Preliminary report of a randomized, double-blind placebo-controlled trial of a Chinese herbal medicine preparation CH-100 in the treatment of chronic hepatitis C.
Batey RG, Bensoussan A, Fan YY, Bollipo S, Hossain MA; Department of Gastroenterology, John Hunter Hospital, Newcastle, New South Wales, Australia. RBatey@doh.health.nsw.gov.au

The treatment of chronic hepatitis C is relatively unsatisfactory and many patients have turned to unproven alternative medicines to modify the course of their illness. We report a study of a Chinese herbal medicine preparation CH-100 in the management of chronic hepatitis C. Patients with documented chronic hepatitis C were randomly allocated to receive active herbal or placebo tablets (five tablets thrice daily). Patients were followed monthly and evaluated by a Western and a traditional Chinese medical practitioner. Therapy was monitored by measurement of liver function tests, creatinine and full blood count on a monthly basis. Twenty patients in each group were well matched for age, sex, duration of illness, previous interferon therapy and alcohol intake. Active Chinese herbal medication was associated with a significant reduction in alanine aminotransferase (ALT) levels over the 6 month study period (P less than 0.03). No patient cleared the virus but four normalized their ALT on treatment. Appropriately prescribed Chinese herbal medicine may have a role in the management of chronic hepatitis C and further controlled studies are indicated.

Advertisement
Hepatitis C Primer Home

What is Hepatitis How is Hepatitis Transmitted

Long-term Prognosis

Complications of HCV Liver Biopsy Treatment Info (Interferon, Herbal, etc) Lab Tests (PCR, Genotype,etc.) Nutrition & Alternative Info

Patient Information (Support Groups, Doctor Listing, etc) Related Webpages Transplant Info Site Search HCV Webrings Guestbook FAQ & Disclaimers

Key Findings About HCV Genotype 3
Learn about the clinical data which suggests that interferon-free regimens containing Gilead's Sovaldi (sofosbuvir) and Bristol-Myers Squibb's NS5A inhibitor daclatasvir have advantages over currently available regimens for HCV genotype-3 infections.

Diet Supplement Tied to Hepatitis
Did you know that close to 100 people have unintentionally suffered from hepatitis because they took a popular weight loss product?

New Hepatitis C Study Cures 90% of Patients
Learn more about the combination of two anti-viral drugs (daclatasvir and asunaprevir) developed by Bristol-Myers Squibb Co that has been highly effective and well tolerated among study participants.

More Hep C articles ...